Asian bioclusters ranked with China at the top spot

Top bio clusters
Ranking

Eight Asian nations rushing to build the infrastructure that will bring in biotechs both large and small have been ranked by Genetic Engineering & Biotechnology News (GEN) in its annual effort using 5 number-based criteria.

Of course the ingredients that go into the major life science hubs in Boston or Silicon Valley in the U.S. can be tallied as well--but other intangible ingredients from the quality of nearby universities and lifestyle to capital access are often ranked as the most critical factors.

But using the GEN criteria--public R&D spending, patents, IPOs, number of companies and jobs--China hits 4 out 5, placing it easily in the top spot.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"Keeping China on top in R&D is among priorities of the new 13th Five-Year Plan that took effect this year," the scientific news site said.

"It encourages biopharma to expand development programs in 'order to strengthen the prevention and cure of infectious, chronic, and endemic diseases,' and sets the stage for a new competitive grant program to fund stem cell and translational research. The world’s most populous nation is also the leader in IPOs ($1.936 billion raised by 14 companies), as well in number of companies (7,500, of which at least 5,000 are pharmaceuticals), and jobs."

Japan held second place as leading drug companies expand research pacts with universities and national laboratories, GEN said, though new companies clearly lag behind the pace in China.

In something of a surprise, India pipped heavy state spenders such as South Korea and Singapore with startups that once sought easier regulatory and business conditions now staying home.

Rounding out the remaining 5 spots in order were South Korea, Taiwan, Australia, Singapore and Malaysia.

- here's the story

Suggested Articles

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.